- Home
- DVS vs FULC Comparison
DVS vs FULC Comparison
Compare DVS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DVS | FULC |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.2M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | DVS | FULC |
|---|---|---|
| Price | $4.38 | $9.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 02-23-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $2.30 | $2.32 |
| 52 Week High | $5.38 | $15.74 |
Technical Indicators
Market Signals| Indicator | DVS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 40.87 |
| Support Level | $4.29 | $9.77 |
| Resistance Level | $4.93 | $10.47 |
| Average True Range (ATR) | 0.24 | 0.70 |
| MACD | -0.06 | -0.32 |
| Stochastic Oscillator | 11.04 | 8.63 |
Price Performance
Historical ComparisonAbout DVS Dolly Varden Silver Corporation
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.